Taken together, the results of this study provide important new evidence that RNAi-mediated suppression of α-synuclein in the primate brain is feasible and relatively safe and should therefore be further pursued for therapeutic purposes against human α-synucleinopathies. This evidence concerns the gene SNCA and synucleinopathy.